Sphingolipids in thyroid eye disease

Front Endocrinol (Lausanne). 2023 Apr 4:14:1170884. doi: 10.3389/fendo.2023.1170884. eCollection 2023.

Abstract

Graves' disease (GD) is caused by an autoimmune formation of autoantibodies and autoreactive T-cells against the thyroid stimulating hormone receptor (TSHR). The autoimmune reaction does not only lead to overstimulation of the thyroid gland, but very often also to an immune reaction against antigens within the orbital tissue leading to thyroid eye disease, which is characterized by activation of orbital fibroblasts, orbital generation of adipocytes and myofibroblasts and increased hyaluronan production in the orbit. Thyroid eye disease is the most common extra-thyroidal manifestation of the autoimmune Graves' disease. Several studies indicate an important role of sphingolipids, in particular the acid sphingomyelinase/ceramide system and sphingosine 1-phosphate in thyroid eye disease. Here, we discuss how the biophysical properties of sphingolipids contribute to cell signaling, in particular in the context of thyroid eye disease. We further review the role of the acid sphingomyelinase/ceramide system in autoimmune diseases and its function in T lymphocytes to provide some novel hypotheses for the pathogenesis of thyroid eye disease and potentially allowing the development of novel treatments.

Keywords: Graves’ disease; acid sphingomyelinase 2; ceramide; sphingolipids; thyroid eye disease (TED).

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoimmune Diseases*
  • Ceramides
  • Graves Disease*
  • Graves Ophthalmopathy*
  • Humans
  • Sphingolipids
  • Sphingomyelin Phosphodiesterase

Substances

  • Sphingomyelin Phosphodiesterase
  • Sphingolipids
  • Ceramides

Grants and funding

The manuscript was supported by DFG grant Gu 335/35-2 to EG.